Research programme: cancer therapeutics - Pelican Therapeutics

Drug Profile

Research programme: cancer therapeutics - Pelican Therapeutics

Alternative Names: PTX-15; PTX-25; PTX-35

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pelican Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Proteins
  • Mechanism of Action T lymphocyte stimulants; Tumour necrosis factor member 25 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Apr 2018 Heat Biologics plans to file an IND for PTX 35 in the first quarter of 2019
  • 18 Apr 2018 Heat Biologics plans a clinical trial in the first quarter of 2019
  • 04 Oct 2017 Pelican Therapeutics and Selexis enters into service agreement for SUREtechnologyPlatform™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top